Trade Alert for June 7th, 2013. Resistance past. Big Block @45k taken out. Watch for higher move. Alert for Members ONLY, possible higher move. (Moved to Public on Saturday, June 8th) Trade alert – big block of @45k at resistance…
Free Trade Alerts
I bought $BDSI.. Chart with basic DD
BDSI is such a compelling prospect for a short term investment for a couple of different reasons. The most important reason being a major catalyst coming mid 2013. BDSI is anticipating a mid-year filing of an NDA for BUNAVAIL(tm) for the…
Trading call: $OPXA- Price target opinion – $2.50
Trading call: $OPXA- Price target opinion – $2.50 More coverage to come
$ACRX Trade Call – Target $5.75
$ACRX Trade Call – Target $5.75 Accumulation, MACD and RSI are trending upwards per the 3 day 10 minute chart above. Lots of good things ahead for ACRX. I think my $5.75 target is low like it was for $TSRX…
$TSRX trade call target = $6 + data coming, more DD to follow
Trius Therapeutics (TSRX) I bought $TSRX trade call target = $6 + Trius is expecting top-line data from its 2nd Phase III trial of Tedizolid (TR-701) vs. Linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI)…
Trade Alert: Bought $DARA – Price Target opinion = $1.35 – $1.45
More DD to come, for reference, please see http://seekingalpha.com/article/1156481-imminent-catalysts-should-keep-investor-interest-alive-for-dara-biosciences?source=yahoo http://seekingalpha.com/article/1042311-dara-the-future-of-oncology-biopharma-on-the-cheap?source=yahoo http://seekingalpha.com/article/866781-time-to-buy-dara-bio The above chart shows me a cup and handle almost complete. I like the last 3 candles. As those of you know who listen to my show, I…
Trade and buy Alert, Bought $CORT at 2.00, target opinion per chart = $2.50 short term.
Trade and buy Alert, Bought $CORT at $2.00, target opinion per chart = $2.50 short term. Pinched chart making a bounce back, minimal resistance til $2.50
Alert: I bought ArQule Inc. $ARQL
ArQule Inc. (ARQL) Price: $2.86 Market Cap: $178.30M My price target opinion into January 13, $4.00 Catalyst: Tivantinib ArQule has advanced into Phase 3 clinical development with its lead product, tivantinib (ARQ 197), an orally available, small molecule that inhibits…